Study in Patients With Advanced Cancers Associated With Expression of DLL3
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04471727 |
Recruitment Status :
Recruiting
First Posted : July 15, 2020
Last Update Posted : December 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Small-cell Lung Cancer | Drug: HPN328 Drug: Atezolizumab | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 162 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3) |
Actual Study Start Date : | December 29, 2020 |
Estimated Primary Completion Date : | January 2024 |
Estimated Study Completion Date : | June 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: HPN328 monotherapy dose escalation
HPN328 will be administered as a single agent once weekly via IV infusion during each 21 day cycle.
|
Drug: HPN328
HPN328 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains |
Experimental: HPN328 monotherapy dose escalation with extended dosing intervals
HPN328 will be administered as a single agent, via IV infusion either once every 2 weeks (28-day cycle), or once every 3 weeks (21-day cycle).
|
Drug: HPN328
HPN328 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains |
Experimental: HPN328 dose escalation in combination with atezolizumab
SCLC patients will be treated with a combination regimen of HPN328 and atezolizumab. HPN328 will be administered once every 2 weeks via IV infusion during each 28-day cycle. Atezolizumab will be administered once every 4 weeks via IV infusion on Day 1 of each 28-day cycle.
|
Drug: HPN328
HPN328 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains Drug: Atezolizumab Atezolizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody which potently and selectively inhibits binding of programmed death receptor 1 ligand (PD-L1) on tumor cells and tumor infiltrating immune cells in the tumor microenvironment |
- Frequency and severity of treatment-emergent AEs (TEAEs) graded according to NCI CTACAE version 5.0 (ASTCT grading criteria for CRS and ICANS). [ Time Frame: Up to 4 years ]
- Number and severity of DLTs following treatment with HPN328 as monotherapy or in combination with atezolizumab. [ Time Frame: Up to 4 years ]
- PK parameters of HPN328 as monotherapy or in combination with atezolizumab. [ Time Frame: Up to 4 years ]
- Single dose - maximum concentration, time to maximum concentration, area under the single dose concentration-time curve over the dosing interval, area under the concentration-time curve extrapolated to infinity, terminal elimination half-life, and clearance as data permit
- Multiple dose (assuming stead state is achieved) - maximum concentration at steady state, time to maximum concentration, area under the steady state concentration-time curve over dosing interval, terminal elimination half-life, minimum concentration, clearance, volume of distribution, and accumulation ratio as data permit.
- Change from baseline in selected clinical laboratory parameters, vital signs, and ECGs. [ Time Frame: Up to 4 years ]
- Objective response rate (ORR) based on RECIST v1.1 (PCWG3 for patients with NEPC) [ Time Frame: Up to 4 years ]
- Extra-cranial objective response rate (EC-ORR) based on modified RECIST v1.1 [ Time Frame: Up to 4 years ]
- Best Overall Response (BOR) [ Time Frame: Up to 4 years ]
- Progression-free survival (PFS) [ Time Frame: Up to 4 years ]
- Extra-cranial progression free survival (EC-PFS) [ Time Frame: Up to 4 years ]
- Overall survival (OS) [ Time Frame: Up to 4 years ]
- Duration of response (DOR) [ Time Frame: Up to 4 years ]
- Duration of extra-cranial response (EC-DOR) [ Time Frame: Up to 4 years ]
- Incidence and titers of ADAs against HPN328 and atezolizumab (for combination-treatment patients) [ Time Frame: Up to 4 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Major Inclusion Criteria:
-
Histologically or cytologically confirmed malignancy associated with expression of DLL3:
- SCLC which is relapsed/refractory following at least 1 prior line of systemic therapy that included platinum-based chemotherapy
- Neuroendocrine Prostate Cancer (NEPC; de novo or treatment-emergent) which is relapsed/refractory to standard systemic therapy
- High-grade neuroendocrine tumor types other than SCLC and NEPC has at least of the following:
- Disease that is relapsed/refractory to standard systemic therapy,
- Disease for which standard therapy does not exist, or
- Disease for which standard therapy is not considered appropriate by the Investigator
-
Available archival tissue sample or fresh biopsy tissue sample
- For SCLC and NEPC: must be available for shipment prior to enrollment but confirmation of DLL3 expression is not required prior to enrollment.
- For high-grade neuroendocrine tumor types other than SCLC and NEPC: demonstration of DLL3 expression in a tumor sample is required and must be confirmed prior to screening.
-
Adequate hematologic status, including:
- Absolute neutrophil count (ANC) ≥1500 cells/μL
- Platelet count ≥100,000/μL
- Hemoglobin ≥9 g/dL (no transfusions allowed within 2 weeks prior to screening)
-
Adequate renal function, including:
• Calculated creatinine clearance ≥50 mL/min using the formula of Cockcroft and Gault
-
Adequate liver function, including
- Total bilirubin ≤1.5 x upper limit of normal (ULN), regardless of direct bilirubin, unless the patient has documented Gilbert syndrome in which case the maximum total serum bilirubin should be 5 mg/dL
- Aspartate and alanine transaminase (AST and ALT) ≤3 x ULN
Major Exclusion Criteria:
- Untreated central nervous system (CNS) metastases. Patients with history of CNS metastases can participate provided they are pretreated and radiologically stable (i.e., without evidence of progression) for at least 2 weeks by repeated imaging (note: repeated imaging should be performed during study screening), asymptomatic, and without requirement of steroid treatment for at least 7 days before the first dose of study treatment.
- Patients with glioma or other primary CNS malignancy.
- Patients with spinal cord compression or symptomatic/uncontrolled epidural disease. Patients with previously treated spinal cord compression or epidural disease may be eligible if stable for at least 1 week prior to first dose of study drug.
- History of intracranial hemorrhage or spinal cord hemorrhage.
- Active neurologic paraneoplastic syndrome.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (e.g., biweekly or more frequently).
- Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis. Exceptions apply.
- Ongoing treatment with immunosuppressive medications (including, but not limited to, systemic corticosteroids [prednisone dose >10mg per day or equivalent], cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] alpha agents) within 2 weeks prior to initiation of treatment, or anticipation of need for systemic immunosuppressive medication during study treatment (except protocol-required pre-medications). Exceptions apply.
- History of allogeneic stem cell transplant or solid-organ transplant.
-
For patients enrolled in the HPN328/Atezolizumab combination cohorts:
- Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, or other anti-PD-(L)1 agents.
- Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment.
- History of severe anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT). History of radiation pneumonitis in the radiation field is permitted.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04471727
Contact: Harpoon ClinicalTrials.gov Contact | (650) 452-7280 | hpn328_4001ctgov@harpoontx.com |
United States, California | |
Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Recruiting |
Los Angeles, California, United States, 90048 | |
Contact: Garrett Crook 424-314-0745 Garrett.Crook@cshs.org | |
Principal Investigator: Kanya Sankar, MD | |
University of California San Francisco | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Christopher De Leon 415-307-9861 chris.deleon@ucsf.edu | |
United States, Colorado | |
University of Colorado | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Emma Filar 702-848-9206 EMMA.FILAR@CUANSCHUTZ.EDU | |
Principal Investigator: Erin Schenk, MD | |
United States, Massachusetts | |
Dana Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02467 | |
Contact: Himisha Beltran, MD 617-632-2429 Himisha_Beltran@DFCI.HARVARD.EDU | |
Principal Investigator: Himisha Beltran, MD | |
United States, Michigan | |
Karmanos Cancer Center | Recruiting |
Detroit, Michigan, United States, 48201 | |
Contact: Aaron Le 313-576-8912 lea@karmanos.org | |
Principal Investigator: Hirva Mamdani, MD | |
United States, New York | |
Roswell Park Comprehensive Cancer Center | Recruiting |
Buffalo, New York, United States, 14263 | |
Contact: Janine Miller 716-845-2809 janine.miller@RoswellPark.org | |
Principal Investigator: Prantesh Jain, MD | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10021 | |
Contact: Noura Choudury, MD choudhn2@mskcc.org | |
Principal Investigator: Noura Choudury, MD | |
United States, Ohio | |
University Hospitals Cleveland Medical Center | Recruiting |
Cleveland, Ohio, United States, 44106 | |
Contact: Cancer Information Services 800-641-2422 Kyle.Logue@uhhospitals.org | |
Principal Investigator: Afshin Dowlati, MD | |
United States, Oregon | |
Providence | Recruiting |
Portland, Oregon, United States, 97213 | |
Contact CanRsrchStudies@providence.org | |
Principal Investigator: Rachel Sanborn, MD | |
United States, Tennessee | |
Tennessee Oncology | Recruiting |
Nashville, Tennessee, United States, 37203 | |
Contact: Tennessee Oncology Sarah Cannon Research Institute 615-329-7478 cann.researchreferrals@scresearch.net | |
Principal Investigator: Melissa L. Johnson, MD | |
United States, Wisconsin | |
Medical College of Wisconsin | Recruiting |
Milwaukee, Wisconsin, United States, 53226 | |
Contact: Jonathan Thompson, MD jrthomps@mcw.edu | |
Principal Investigator: Jonathan Thompson, MD |
Responsible Party: | Harpoon Therapeutics |
ClinicalTrials.gov Identifier: | NCT04471727 |
Other Study ID Numbers: |
HPN328-4001 |
First Posted: | July 15, 2020 Key Record Dates |
Last Update Posted: | December 12, 2023 |
Last Verified: | December 2023 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Cancer Small-Cell Lung Cancer DLL3 Harpoon TriTAC |
Prostate Cancer Neuroendocrine Tumors High Grade Neuroendrocrine Features Delta Like Canonical Notch Ligand 3 |
Lung Neoplasms Small Cell Lung Carcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Atezolizumab Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Antineoplastic Agents |